Other Income

9 Months Ended

Sep. 30, 2024

Other Income

Other Income

15. Other Income

	Nine month period
	ended September 30,
	2024	2023
	€1.000	€1.000
Grant income	504	76
Other income	—	4
	504	80

In January, 2024, the Company entered into an agreement with the Rett Syndrome Research Trust (“RSRT”) that focuses on the design and development of editing oligonucleotides (“EONs”) using the Company’s Axiomer technology platform targeting the transcription factor Methyl CpG binding protein 2 (“MECP2”) and correcting mutations of interest. Under the agreement, RSRT awarded the Company up to € 1,015,000 as a research grant for the initial phase of the project.

Grants are recognized in other income in the same period in which the related R&D costs are recognized.